Immunopathogenesis of the multiple sclerosis lesion

  • Silva Markovic-Plese
  • Henry F. McFarland


Multiple sclerosis (MS) is thought to be an autoimmune disease with a chronic inflammatory response directed against central nervous system (CNS) myelin antigens. Immunologic studies indicate that autoreactive CD4+ lymphocytes migrate into the CNS causing blood brain barrier (BBB) disruption, an initial event in the evolution of the MS lesion. Subsequent antigen recognition within the CNS initiates inflammatory responses that, through the multiple effector mechanisms, lead to demyelination. Magnetic resonance imaging (MRI) studies provide new insights into the evolution of the MS lesion, revealing an active and continuous pathologic process that is not only localized to focal lesions, but also diffusely affects normal appearing white matter (NAWM). Standard T2-weighted images are exquisitely sensitive, showing changes due to inflammation, edema, demyelination, and axonal loss, but because of the lack of pathologic specificity, they only moderately correlate with the clinical parameters. New MRI techniques, including magnetic resonance spectroscopy, magnetization transfer, and diffusion imaging, provide a better measure of axonal loss and demyelination, the most clinically relevant components of MS lesions. Hopefully, they will enable us to more accurately monitor disease activity and evaluate the effects of new therapies on the progression of the disease.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Cannella B, Raine CS: The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995, 37:424–435.PubMedCrossRefGoogle Scholar
  2. 2.
    Bo L, Mork S, Kong PA, et al.: Detection of MHC class IIantigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 1994, 51:135–146.PubMedCrossRefGoogle Scholar
  3. 3.
    Babbe H, Roers A, Waisman A, et al.: Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000, 192:393–404. T-cell receptor repertoire of CD4+ and CD8+ cells infiltrating actively demyelinating multiple sclerosis (MS) lesions was determined at the single cell level. Expanded CD8+ T-cell clones were predominantly identified in MS lesions.PubMedCrossRefGoogle Scholar
  4. 4.
    Cross AH, Cannella B, Brosnan CF, et al.: Homing to central nervous system vasculature by antigen-specific lymphocytes. I. Localization of 14C-labeled cells during acute, chronic, and relapsing experimental allergic encephalomyelitis. Lab Invest 1990, 63:162–170.PubMedGoogle Scholar
  5. 5.
    Lucchinetti C, Bruck W, Parisi J, et al.: A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999, 122:2279–2295.PubMedCrossRefGoogle Scholar
  6. 6.
    Scolding N, Franklin R, Stevens S, et al.: Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain 1998, 121:2221–2228.PubMedCrossRefGoogle Scholar
  7. 7.
    Trapp BD, Peterson J, Ransohoff RM, et al.: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278–285.PubMedCrossRefGoogle Scholar
  8. 8.
    Ferguson B, Matyszak MK, Esiri MM, et al.: Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120:393–399.PubMedCrossRefGoogle Scholar
  9. 9.
    Bielekova B, Goodwin B, Richert N, et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167–1175. In this clinical trial, the treatment with altered peptide ligand adversely increased the frequency of T cells cross-reactive with myelin basic protein epitope 83–99.PubMedCrossRefGoogle Scholar
  10. 10.
    Scholz C, Patton KT, Anderson DE, et al.: Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 1998, 160:1532–1538.PubMedGoogle Scholar
  11. 11.
    Lovett-Racke AE, Trotter JL, Lauber J, et al.: Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 1998, 101:725–730.PubMedCrossRefGoogle Scholar
  12. 12.
    Schirmer M, Vallejo AN, Weyand CM, et al.: Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28-T cells from rheumatoid arthritis patients. J Immunol 1998, 161:1018–1025.PubMedGoogle Scholar
  13. 13.
    Tivol EA, Borriello F, Schweitzer AN, et al.: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541–547.PubMedCrossRefGoogle Scholar
  14. 14.
    Bachmaier K, Krawczyk C, Kozieradzki I, et al.: Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 2000, 403:211–216.PubMedCrossRefGoogle Scholar
  15. 15.
    Thornton AM, Shevach EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998, 188:287–296.PubMedCrossRefGoogle Scholar
  16. 16.
    Read S, Malmstrom V, Powrie F: Cytotoxic T lymphocyteassociated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192:295–302.PubMedCrossRefGoogle Scholar
  17. 17.
    Hemmer B, Gran B, Zhao Y, et al.: Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med 1999, 5:1375–1382. In a patient with chronic neuroborreliosis, the authors identified a range of T-cell ligands from Borrelia burgdorferi and self-tissues.PubMedCrossRefGoogle Scholar
  18. 18.
    Challoner PB, Smith KT, Parker JD, et al.: Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 1995, 92:7440–7444.PubMedCrossRefGoogle Scholar
  19. 19.
    Sriram S, Stratton CW, Yao S, et al.: Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999, 46:6–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Hemmer B, Vergelli M, Gran B, et al.: Predictable TCR antigen recognition based on peptide scans leads to the identification of agonist ligands with no sequence homology. J Immunol 1998, 160:3631–3666.PubMedGoogle Scholar
  21. 21.
    Evans CF, Horwitz MS, Hobbs MV, et al.: Viral infection of transgenic mice expressing a viral protein in oligodendrocytes leads to chronic central nervous system autoimmune disease. J Exp Med 1996, 184:2371–2384.PubMedCrossRefGoogle Scholar
  22. 22.
    Horwitz MS, Bradley LM, Harbertson J, et al.: Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998, 4:781–785.PubMedCrossRefGoogle Scholar
  23. 23.
    Carrithers MD, Visintin I, Kang SJ, et al.: Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 2000, 123:1092–1101.PubMedCrossRefGoogle Scholar
  24. 24.
    Hickey WF, Hsu BL, Kimura H: T-lymphocyte entry into the central nervous system. J Neurosci Res 1991, 28:254–260.PubMedCrossRefGoogle Scholar
  25. 25.
    Brabb T, von Dassow P, Ordonez N, et al.: In situ tolerance within the central nervous system as a mechanism for preventing autoimmunity. J Exp Med 2000, 192:871–880.PubMedCrossRefGoogle Scholar
  26. 26.
    Krakowski ML, Owens T: Naive T lymphocytes traffic to inflamed central nervous system, but require antigen recognition for activation. Eur J Immunol 2000, 30:1002–1009.PubMedCrossRefGoogle Scholar
  27. 27.
    Sallusto F, Lenig D, Forster R, et al.: Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708–712.PubMedCrossRefGoogle Scholar
  28. 28.
    Strunk T, Bubel S, Mascher B, et al.: Increased numbers of CCR5+ interferon-gamma- and tumor necrosis factoralpha-secreting T lymphocytes in multiple sclerosis patients. Ann Neurol 2000, 47:269–273.PubMedCrossRefGoogle Scholar
  29. 29.
    Lucchinetti C, Bruck W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707–717. A pathologic study on a large number of actively demyelinating lesions indicates a very heterogenous nature of multiple sclerosis lesions.PubMedCrossRefGoogle Scholar
  30. 30.
    Genain CP, Cannella B, Hauser SL, et al.: Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 1999, 5:170–175.PubMedCrossRefGoogle Scholar
  31. 31.
    Wolswijk G: Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain 2000, 123:105–515.PubMedCrossRefGoogle Scholar
  32. 32.
    Yao DL, Liu X, Hudson LD, et al.: Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis. Life Sci 1996, 58:1301–1306.PubMedCrossRefGoogle Scholar
  33. 33.
    McDonald JW, Liu XZ, Qu Y, et al.: Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med 1999, 5:1410–1412.PubMedCrossRefGoogle Scholar
  34. 34.
    Bitsch A, Schuchardt J, Bunkowski S, et al.: Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000, 123:1174–1183.PubMedCrossRefGoogle Scholar
  35. 35.
    Smith ME, Stone LA, Albert PS, et al.: Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993, 33:480–489.PubMedCrossRefGoogle Scholar
  36. 36.
    O’Riordan JI, Thompson AJ, Kingsley DP, et al.: The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998, 121:495–503.PubMedCrossRefGoogle Scholar
  37. 37.
    Filippi M, Iannucci G, Tortorella C, et al.: Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 1999, 52:588–594.PubMedGoogle Scholar
  38. 38.
    Brex PA, O’Riordan JI, Miszkiel KA, et al.: Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 1999, 53:1184–1190.PubMedGoogle Scholar
  39. 39.
    Lee MA, Smith S, Palace J, et al.: Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain 1999, 122:1261–1270.PubMedCrossRefGoogle Scholar
  40. 40.
    Filippi M, Yousry T, Horsfield MA, et al.: A high-resolution three-dimensional T1-weighted gradient echo sequence improves the detection of disease activity in multiple sclerosis. Ann Neurol 1996, 40:901–907.PubMedCrossRefGoogle Scholar
  41. 41.
    Filippi M, Rocca MA, Martino G, et al.: Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998, 43:809–814.PubMedCrossRefGoogle Scholar
  42. 42.
    Stevenson VL, Leary SM, Losseff NA, et al.: Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998, 51:234–238.PubMedGoogle Scholar
  43. 43.
    Werring DJ, Brassat D, Droogan AG, et al.: The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 2000, 123:1667–1676.PubMedCrossRefGoogle Scholar
  44. 44.
    De Stefano N, Narayanan S, Matthews PM, et al.: In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999, 122:1933–1939.PubMedCrossRefGoogle Scholar
  45. 45.
    Sarchielli P, Presciutti O, Pelliccioli GP, et al.: Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 1999, 122:513–521.PubMedCrossRefGoogle Scholar
  46. 46.
    Jacobs LD, Beck RW, Simon JH, et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000, 343:898–904.PubMedCrossRefGoogle Scholar
  47. 47.
    Truyen L, van Waesberghe JH, van Walderveen MA, et al.: Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996, 47:1469–1476.PubMedGoogle Scholar
  48. 48.
    Fox NC, Jenkins R, Leary SM, et al.: Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 2000, 54:807–812.PubMedGoogle Scholar

Copyright information

© Current Science Inc. 2001

Authors and Affiliations

  • Silva Markovic-Plese
    • 1
  • Henry F. McFarland
    • 1
  1. 1.Neuroimmunology BranchNational Institute for Neurological Diseases and Stroke, National Institutes of HealthBethesdaUSA

Personalised recommendations